Herantis CEO outlines development plan for Parkinson's drug

Pekka Simula, CEO of Herantis, a company born from the merger of Hermo Pharma and Laurantis Pharma, talks to Scrip about the group's lead asset in Parkinson's disease. Simula also discusses Herantis's early-stage asset, which is being pursued as a treatment for secondary lymphedema.